Mission
Dapharco (DHG Pharma) is committed to providing high-quality products and services to fulfill the aspiration for a healthier and more beautiful life.

Trade Name: DHG Pharma · Healthcare – Pharmaceuticals · Can Tho
Enterprise manufacturing and trading pharmaceuticals, health supplements, and cosmeceuticals.
DHG Pharmaceutical Joint-Stock Company (DHG Pharma) was formerly known as 2/9 Pharmaceutical State Enterprise, established in 1974 in Can Tho. In 2004, the DHG Pharmaceutical Union was equitized into DHG Pharmaceutical Joint-Stock Company; DHG shares have been listed on the HOSE since 2006.
Since 2019, Taisho Pharmaceutical (Japan) has held a 51.01% stake and become the controlling shareholder; in 2020, the company increased its foreign ownership limit to 100%. Charter capital is currently approximately 1.307 trillion VND.
DHG Pharma manufactures western medicines across 9 main groups (antibiotics, analgesics – antipyretics, respiratory, digestive – hepatobiliary, neurological – ophthalmological, cardiovascular – diabetes, nutritional, musculoskeletal, skincare) along with health supplements; notable brands include Hapacol, Naturenz, Bipp, and NattoEnzym. The Non-Betalactam factory has 3 lines that achieved EU-GMP, and the company has 4 lines that achieved Japan-GMP; the new Betalactam factory has been in operation since May 2024.
According to the 2024 annual report, the distribution system consists of 34 branches nationwide and 3 central warehouses, serving approximately 30,000 pharmacies and about 3,200 hospitals, clinics, medical centers, and major pharmacy chains.
Dapharco (DHG Pharma) is committed to providing high-quality products and services to fulfill the aspiration for a healthier and more beautiful life.
For a healthier and more beautiful life.
Domestic market: pharmacies, hospitals, clinics, medical centers, and pharmacy chains nationwide
Capability information declared by the company; VBC has verified the registration details but does not assess product quality.